These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35113892)

  • 21. Barriers and Facilitators to Long-Acting Injectable HIV Pre-Exposure Prophylaxis Implementation in Primary Care Since Its Approval in the United States.
    Keddem S; Thatipelli S; Caceres O; Roder N; Momplaisir F; Cronholm P
    J Acquir Immune Defic Syndr; 2024 Apr; 95(4):370-376. PubMed ID: 38133586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interest in Long-Acting Injectable Pre-exposure Prophylaxis (LAI PrEP) Among Women in the Women's Interagency HIV Study (WIHS): A Qualitative Study Across Six Cities in the United States.
    Philbin MM; Parish C; Kinnard EN; Reed SE; Kerrigan D; Alcaide ML; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Metsch LR
    AIDS Behav; 2021 Mar; 25(3):667-678. PubMed ID: 32910351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most.
    Philbin MM; Bergen S; Parish C; Kerrigan D; Kinnard EN; Reed S; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Vaughn M; Gutierrez JI; Fischl MA; Alcaide M; Metsch LR
    AIDS Behav; 2022 Apr; 26(4):1260-1269. PubMed ID: 34648131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.
    Psaros C; Goodman GR; Lee JS; Rice W; Kelley CF; Oyedele T; Coelho LE; Phanuphak N; Singh Y; Middelkoop K; Griffith S; McCauley M; Rooney J; Rinehart AR; Clark J; Go V; Sugarman J; Fields SD; Adeyeye A; Grinsztejn B; Landovitz RJ; Safren SA;
    J Int AIDS Soc; 2024 May; 27(5):e26252. PubMed ID: 38783534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individual, social, and structural factors affecting antiretroviral therapy adherence among HIV-positive people who inject drugs in Kazakhstan.
    Davis A; McCrimmon T; Dasgupta A; Gilbert L; Terlikbayeva A; Hunt T; Primbetova S; Wu E; Darisheva M; El-Bassel N
    Int J Drug Policy; 2018 Dec; 62():43-50. PubMed ID: 30359872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials.
    Mantsios A; Murray M; Karver TS; Davis W; Galai N; Kumar P; Swindells S; Bredeek UF; García RR; Antela A; Gomis SC; Bernáldez MP; Czarnogorski M; Hudson K; Walters N; Kerrigan D
    BMC Health Serv Res; 2021 Mar; 21(1):255. PubMed ID: 33743684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient Education and Decision Support for Long-Acting Injectable HIV Antiretroviral Therapy: Protocol for Tool Development and Pilot Testing with Ryan White HIV/AIDS Program Medical Case Management Programs in New York.
    Irvine MK; Zimba R; Avoundjian T; Peterson M; Emmert C; Kulkarni SG; Philbin MM; Kelvin EA; Nash D
    JMIR Res Protoc; 2024 Mar; 13():e56892. PubMed ID: 38536227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy.
    Benning L; Mantsios A; Kerrigan D; Coleman JS; Golub E; Blackstock O; Konkle-Parker D; Philbin M; Sheth A; Adimora AA; Cohen MH; Seidman D; Milam J; Kassaye SG; Taylor T; Murray M
    BMC Womens Health; 2020 Jul; 20(1):152. PubMed ID: 32711509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human immunodeficiency virus infection challenges: Current therapeutic limitations and strategies for improved management through long-acting injectable formulation.
    Tanushree ; Sharma A; Monika ; Singh RP; Jhawat V
    Rev Med Virol; 2024 Jul; 34(4):e2563. PubMed ID: 38886179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV.
    Simoni JM; Beima-Sofie K; Mohamed ZH; Christodoulou J; Tapia K; Graham SM; Ho R; Collier AC
    AIDS Patient Care STDS; 2019 Mar; 33(3):104-111. PubMed ID: 30844308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic.
    Christopoulos KA; Grochowski J; Mayorga-Munoz F; Hickey MD; Imbert E; Szumowski JD; Dilworth S; Oskarsson J; Shiels M; Havlir D; Gandhi M
    Clin Infect Dis; 2023 Feb; 76(3):e645-e651. PubMed ID: 35913500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Qualitative analysis of barriers and facilitators encountered by HIV patients in an ART adherence programme.
    Krummenacher I; Spencer B; Du Pasquier S; Bugnon O; Cavassini M; Schneider MP
    Int J Clin Pharm; 2014 Aug; 36(4):716-24. PubMed ID: 24913358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation challenges for long-acting antivirals as treatment.
    Havlir D; Gandhi M
    Curr Opin HIV AIDS; 2015 Jul; 10(4):282-9. PubMed ID: 26049955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment among People Living with HIV.
    Matza LS; Paulus TM; Garris CP; Van de Velde N; Chounta V; Deger KA
    Patient; 2020 Aug; 13(4):409-422. PubMed ID: 32356146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Willingness to Use Long-Acting Injectable PrEP Among PrEP Naïve Black and Hispanic Sexual Gender Minority Persons.
    Okafor CN; Eaton L; Watson R
    AIDS Behav; 2024 Jun; 28(6):2166-2174. PubMed ID: 38526639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Lighten This Burden of Ours": Acceptability and Preferences Regarding Injectable Antiretroviral Treatment Among Adults and Youth Living With HIV in Coastal Kenya.
    Simoni JM; Beima-Sofie K; Wanje G; Mohamed ZH; Tapia K; McClelland RS; Ho RJY; Collier AC; Graham SM
    J Int Assoc Provid AIDS Care; 2021; 20():23259582211000517. PubMed ID: 33685272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series.
    Kilcrease C; Yusuf H; Park J; Powell A; Rn LJ; Rn JO; Lmsw BD; Weld ED; Dooley KE; Arrington-Sanders R; Agwu AL
    AIDS Res Ther; 2022 Nov; 19(1):56. PubMed ID: 36435793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A missing perspective: injectable pre-exposure prophylaxis for people who inject drugs.
    Biello KB; Edeza A; Salhaney P; Biancarelli DL; Mimiaga MJ; Drainoni ML; Childs ES; Bazzi AR
    AIDS Care; 2019 Oct; 31(10):1214-1220. PubMed ID: 30822103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EquiPrEP: An implementation science protocol for promoting equitable access and uptake of long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP).
    Kaul CM; Moore BE; Kaplan-Lewis E; Casey E; Pitts RA; Pagan Pirallo P; Lim S; Kapadia F; Cohen GM; Khan M; Mgbako O
    PLoS One; 2023; 18(9):e0291657. PubMed ID: 37725628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.